Menu
  • About RedHill
  • Products
  • Partnering
  • Investors
  • News
  • Contact
  • CAREERS
  • Press Releases

     
    Press Releases
      Date Summary View
    Aug 17, 2017
    RedHill was granted the exclusive rights to promote Esomeprazole Strontium Delayed-Release (DR) Capsules to gastroenterologists in certain U.S. territories          Esomeprazole Strontium DR Capsules 49.3 mg is an FDA-approved, proprietary, pr...
    PDF
    Aug 10, 2017
    RedHill's U.S. gastrointestinal (GI)-focused sales force is promoting two specialty products, setting the stage for the potential launch of RedHill's late clinical-stage GI products, if approved, and for the acquisition of additional commercial GI productsThe ERADICATE Hp2 confirmatory Phase III study with TALICIA...
    PDF
    Jul 31, 2017
    The independent Data and Safety Monitoring Board (DSMB) reviewed safety and efficacy data, of which RedHill remains blinded, from the first 222 subjects who have completed week 26 assessments in the Phase III MAP US study To date, over 300 of the planned 410 subjects, have been randomized in the Phase III MAP US study An open-label extension Phase ...
    PDF
    Jul 25, 2017
    RedHill maintains a debt-free balance sheet with $51 million cash1 at the end of the second quarter of 2017  Select recent milestones include: Initial net revenues of approximately $0.5 million between June 12-30 following commencement of promotional activities in the U.S. by RedHill's GI-focused sales force with two GI specialty products, Do...
    PDF
    Jul 18, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., July 18, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastr...
    PDF
    Jul 17, 2017
    Top-line results are expected in September 2017 The randomized, double-blind, placebo-controlled Phase II study is evaluating the safety and efficacy of BEKINDA® (RHB-102) 12 mg in 127 U.S. patients with diarrhea-predominant irritable bowel syndrome (IBS-D), with a primary endpoint of response in stool consistency as compared to baseline IBS ...
    PDF
    Jul 12, 2017
    The second independent Data and Safety Monitoring Board (DSMB) meeting of the RHB-104 Phase III study for Crohn's disease (MAP US study) is planned to be held in late July 2017 and will assess the safety and efficacy of RHB-104 in the first 222 subjects who have completed week 26 assessmentsThe DSMB meeting will include an interim efficacy analysis...
    PDF
    Jun 19, 2017
    TEL-AVIV, Israel and RALEIGH, N.C., June 19, 2017 (GLOBE NEWSWIRE) -- RedHill Biopharma Ltd. (NASDAQ:RDHL) (Tel-Aviv Stock Exchange:RDHL) ("RedHill" or the "Company"), a specialty biopharmaceutical company primarily focused on late clinical-stage development and commercialization of proprietary, orally-administered, small molecule drugs for gastr...
    PDF
    Jun 15, 2017
    Subject to a successful outcome and any additional regulatory feedback, the confirmatory Phase III study (ERADICATE Hp 2) is expected to complete the package required for a potential U.S. NDA for RHB-105, newly branded as TALICIA™  The two-arm, randomized, double-blind, active comparator, confirmatory Phase III study is planned to enroll 444 ...
    PDF
    Jun 14, 2017
    The positive Phase III top-line results indicate that the study successfully met its primary endpoint and BEKINDA® 24 mg was shown to be effective, safe and well tolerated in patients with acute gastroenteritis and gastritis RedHill will host a conference call and webcast to discuss the top-line results from the BEKINDA® Phase III study ...
    PDF
    Page:
    1
    ... NextLast

    Subscribe to press releases